215 related articles for article (PubMed ID: 35883451)
1. Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.
Pandey SK; Machlof-Cohen R; Santhanam M; Shteinfer-Kuzmine A; Shoshan-Barmatz V
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883451
[TBL] [Abstract][Full Text] [Related]
2. Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder Cancer.
Alhozeel B; Pandey SK; Shteinfer-Kuzmine A; Santhanam M; Shoshan-Barmatz V
Cells; 2024 Apr; 13(7):. PubMed ID: 38607066
[TBL] [Abstract][Full Text] [Related]
3. Rewiring of Cancer Cell Metabolism by Mitochondrial VDAC1 Depletion Results in Time-Dependent Tumor Reprogramming: Glioblastoma as a Proof of Concept.
Arif T; Stern O; Pittala S; Chalifa-Caspi V; Shoshan-Barmatz V
Cells; 2019 Oct; 8(11):. PubMed ID: 31661894
[TBL] [Abstract][Full Text] [Related]
4. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties.
Arif T; Krelin Y; Nakdimon I; Benharroch D; Paul A; Dadon-Klein D; Shoshan-Barmatz V
Neuro Oncol; 2017 Jul; 19(7):951-964. PubMed ID: 28339833
[TBL] [Abstract][Full Text] [Related]
5. Reducing VDAC1 expression induces a non-apoptotic role for pro-apoptotic proteins in cancer cell differentiation.
Arif T; Krelin Y; Shoshan-Barmatz V
Biochim Biophys Acta; 2016 Aug; 1857(8):1228-1242. PubMed ID: 27080741
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States.
Arif T; Paul A; Krelin Y; Shteinfer-Kuzmine A; Shoshan-Barmatz V
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30544833
[TBL] [Abstract][Full Text] [Related]
7. The mitochondrial voltage-dependent anion channel 1 in tumor cells.
Shoshan-Barmatz V; Ben-Hail D; Admoni L; Krelin Y; Tripathi SS
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2547-75. PubMed ID: 25448878
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo.
Koren I; Raviv Z; Shoshan-Barmatz V
Cancer Biol Ther; 2010 Jun; 9(12):1046-52. PubMed ID: 20404552
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Reprograming Via Silencing of Mitochondrial VDAC1 Expression Encourages Differentiation of Cancer Cells.
Arif T; Amsalem Z; Shoshan-Barmatz V
Mol Ther Nucleic Acids; 2019 Sep; 17():24-37. PubMed ID: 31195298
[TBL] [Abstract][Full Text] [Related]
10. Mitochondria and nucleus cross-talk: Signaling in metabolism, apoptosis, and differentiation, and function in cancer.
Shteinfer-Kuzmine A; Verma A; Arif T; Aizenberg O; Paul A; Shoshan-Barmaz V
IUBMB Life; 2021 Mar; 73(3):492-510. PubMed ID: 33179373
[TBL] [Abstract][Full Text] [Related]
11. VDAC1 Silencing in Cancer Cells Leads to Metabolic Reprogramming That Modulates Tumor Microenvironment.
Zerbib E; Arif T; Shteinfer-Kuzmine A; Chalifa-Caspi V; Shoshan-Barmatz V
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200480
[TBL] [Abstract][Full Text] [Related]
12. The expression level of the voltage-dependent anion channel controls life and death of the cell.
Abu-Hamad S; Sivan S; Shoshan-Barmatz V
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5787-92. PubMed ID: 16585511
[TBL] [Abstract][Full Text] [Related]
13. The Voltage-dependent Anion Channel 1 Mediates Amyloid β Toxicity and Represents a Potential Target for Alzheimer Disease Therapy.
Smilansky A; Dangoor L; Nakdimon I; Ben-Hail D; Mizrachi D; Shoshan-Barmatz V
J Biol Chem; 2015 Dec; 290(52):30670-83. PubMed ID: 26542804
[TBL] [Abstract][Full Text] [Related]
14. Clinical implication of voltage-dependent anion channel 1 in uterine cervical cancer and its action on cervical cancer cells.
Wu CH; Lin YW; Wu TF; Ko JL; Wang PH
Oncotarget; 2016 Jan; 7(4):4210-25. PubMed ID: 26716410
[TBL] [Abstract][Full Text] [Related]
15. Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo.
Arif T; Vasilkovsky L; Refaely Y; Konson A; Shoshan-Barmatz V
Mol Ther Nucleic Acids; 2014 Apr; 3(4):e159. PubMed ID: 24781191
[TBL] [Abstract][Full Text] [Related]
16. Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy.
Shteinfer-Kuzmine A; Amsalem Z; Arif T; Zooravlov A; Shoshan-Barmatz V
Mol Oncol; 2018 Jun; 12(7):1077-1103. PubMed ID: 29698587
[TBL] [Abstract][Full Text] [Related]
17. DYNLT1 promotes mitochondrial metabolism to fuel breast cancer development by inhibiting ubiquitination degradation of VDAC1.
Huang L; Wei B; Zhao Y; Gong X; Chen L
Mol Med; 2023 Jun; 29(1):72. PubMed ID: 37280526
[TBL] [Abstract][Full Text] [Related]
18. The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic Link.
Amsalem Z; Arif T; Shteinfer-Kuzmine A; Chalifa-Caspi V; Shoshan-Barmatz V
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331482
[TBL] [Abstract][Full Text] [Related]
19. Knockout of VDAC1 in H9c2 Cells Promotes Oxidative Stress-Induced Cell Apoptosis through Decreased Mitochondrial Hexokinase II Binding and Enhanced Glycolytic Stress.
Yang M; Sun J; Stowe DF; Tajkhorshid E; Kwok WM; Camara AKS
Cell Physiol Biochem; 2020 Sep; 54(5):853-874. PubMed ID: 32901466
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial VDAC1-based peptides: Attacking oncogenic properties in glioblastoma.
Shteinfer-Kuzmine A; Arif T; Krelin Y; Tripathi SS; Paul A; Shoshan-Barmatz V
Oncotarget; 2017 May; 8(19):31329-31346. PubMed ID: 28412744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
